e-learning
resources
Milan 2017
Sunday, 10.09.2017
Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy and safety of nivolumab in routine NSCLC treatment – an observational study in 5 lung cancer centers in Berlin, Germany
D. Misch (Berlin, Germany)
Source:
International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Session:
Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Session type:
Oral Presentation
Number:
1477
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Misch (Berlin, Germany). Efficacy and safety of nivolumab in routine NSCLC treatment – an observational study in 5 lung cancer centers in Berlin, Germany. 1477
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Pemetrexed in the first line treatment in non-small cell lung cancer (NSCLC): A multicentre prospective analysis of data from clinical practise of Czech Republic
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Cost-effectiveness analysis of three strategies of erlotinib treatment in non small-cell lung cancer: A prospective multicentric French study (ERMETIC)
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily at 1250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006
The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting
Source: Eur Respir J 2002; 20: Suppl. 38, 399s
Year: 2002
A three-arm phase III randomised trial assessing, in patients with extensive-disease (ED) small-cell lung cancer (SCLC), accelerated chemotherapy with the support of haematological growth factor or of oral antibiotics
Source: Eur Respir J 2001; 18: Suppl. 33, 319s
Year: 2001
The efficacy and safety of induction chemoradiotherapy (ICRT) followed by surgery in stage III NSCLC patients (pts) with T3/4-adjacent organ invasion involved(AOI): A single-center retrospective observational study.
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
Palliative chemotherapy in non-small cell lung cancer (NSCLC): analysis of UK baseline data from the ACTION observational study
Source: Eur Respir J 2005; 26: Suppl. 49, 11s
Year: 2005
Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005
Palliative chemotherapy in non-small cell lung cancer (NSCLC): first-line therapy data from the ACTION observational study
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005
Real-life effectiveness of first-line treatments in NSCLC patients stage IIIB/IV– data from the Czech TULUNG Registry.
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
Pembrolizumab versus nivolumab as second and further line treatment in non-small cell lung cancer; a retrospective single-centre study
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Use of erlotinib in management of advanced non-small cell lung cancer (NSCLC): The Czech Republic experience with the treatment of a non-selected population of 1735 patients (pts)
Source: Annual Congress 2011 - Treatment of lung cancer
Year: 2011
Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial
Source: Eur Respir J 2007; 30: Suppl. 51, 240s
Year: 2007
Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care.
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019
A study comparing the efficacy, quality of life and toxicity of cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer in the Indian scenario
Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients
Year: 2011
A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Treatment of lung cancer
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept